prevacid iv Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prevacid Iv, and what generic alternatives are available?
Prevacid Iv is a drug marketed by Takeda Pharms Na and is included in one NDA.
The generic ingredient in PREVACID IV is lansoprazole. There are fifty-six drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the lansoprazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prevacid Iv
A generic version of prevacid iv was approved as lansoprazole by MYLAN PHARMS INC on November 10th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for prevacid iv?
- What are the global sales for prevacid iv?
- What is Average Wholesale Price for prevacid iv?
Summary for prevacid iv
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 162 |
Clinical Trials: | 42 |
Patent Applications: | 3,976 |
DailyMed Link: | prevacid iv at DailyMed |
Recent Clinical Trials for prevacid iv
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Janssen Research & Development, LLC | Phase 1 |
McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 |
McGill University Health Center | Phase 4 |
US Patents and Regulatory Information for prevacid iv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Na | PREVACID IV | lansoprazole | INJECTABLE;INTRAVENOUS | 021566-001 | May 27, 2004 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for prevacid iv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Na | PREVACID IV | lansoprazole | INJECTABLE;INTRAVENOUS | 021566-001 | May 27, 2004 | ⤷ Subscribe | ⤷ Subscribe |
Takeda Pharms Na | PREVACID IV | lansoprazole | INJECTABLE;INTRAVENOUS | 021566-001 | May 27, 2004 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for prevacid iv
See the table below for patents covering prevacid iv around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 4589585 | ⤷ Subscribe | |
Denmark | 171340 | ⤷ Subscribe | |
Japan | H0244473 | ⤷ Subscribe | |
Latvia | 5091 | Piridina atvasinajumu iegusanas metode | ⤷ Subscribe |
Netherlands | 930109 | ⤷ Subscribe | |
Philippines | 20946 | PYRIDINE DERIVATIVES AND THEIR PRODUCTION | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 0215908 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for prevacid iv
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1129088 | 2014/008 | Ireland | ⤷ Subscribe | PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919 |
0174726 | 93C0021 | Belgium | ⤷ Subscribe | PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211 |
0328535 | 96C0021 | Belgium | ⤷ Subscribe | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
0174726 | SPC/GB94/011 | United Kingdom | ⤷ Subscribe | SPC/GB94/011, EXPIRES: 20051210 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Prevacid iv Market Analysis and Financial Projection
More… ↓